pharma · Primary Biliary Cirrhosis · Gastric Intestinal Metaplasia
Xijing Hospital of
Xijing Hospital of Digestive Diseases
Xijing Hospital of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Primary Biliary Cirrhosis, Gastric Intestinal Metaplasia. NovaPharmaNews links 2 clinical program(s), 0 drug profil
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Fenofibrate
Phase 3 · small molecule · Primary Biliary Cirrhosis
Fenofibrate for Primary Biliary Cirrhosis is a Phase 3 program (small_molecule) at Xijing Hospital of Digestive Diseases with 1 ClinicalTrials.gov record(s).
Internal code KY20151230-5
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xijing Hospital of Digestive Diseases
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Primary Biliary Cirrhosis
- Status
- active
- Trials
- 1